BCC Research Identifies Epigenetics for Hmt Research as Top Pharma Market
Wellesley, MA (PRWEB) November 22, 2013 -- Epigenetics is an emerging yet rapidly evolving field that offers exciting new opportunities for the diagnosis and treatment of complex clinical disorders. Indeed, the discovery of novel drug candidates for proteins, such as Ezh2, opens enormous possibilities not only in oncology research but in stem cell biology, neurodegeneration, and other diseases.
According to BCC Research's ( http://www.bccresearch.com) report Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery (Report code:PHM128A), increased R&D spending in the development of epigenetic tools and assays for Histone Methyltransferases (HMT) research, HMTs use as biomarkers and targets for diagnostics development and the drug discovery sector will drive tremendous growth in this market for the foreseeable future. BCC Research projects the market to grow to $275 million by 2018, and register a five-year compound annual growth rate of 18.4% from 2013 to 2018.
In addition to comprehensive coverage of the HMTs sector, technical market research reports from BCC Research bring new insights and perspective on the top developments shaping growth in the current pharmaceuticals market, including recent advances in the field of proteasome inhibitors, innovative technologies for disease screening and treatment, developments in the area of cell-based therapeutics, and rapid medical diagnostic field devices that can provide test results in a matter of minutes. The reports provide an overview of the global pharmaceuticals market as well as analyses of five-year market trends with data from 2012, estimates for 2013, and CAGR projections for the period 2013 to 2018.
BCC Research’s in-depth studies also offer evaluations of industry trends and clinical applications for diagnostic tools and treatment products; impact assessment of industry standards and governmental regulations on global markets; as well as comprehensive profiles of the top industry players and relative market shares for leading companies in the industry.
Top Pharmaceutical Sectors
PHM066B - Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery
Ubiquitin proteasome systems represent one of the most studied and challenging areas in basic and applicable science. Recent developments in the field of proteasome inhibitors bring new perspective and alternatives that may change the current market. BCC Research expects the market to reach more than $5.5 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 14.2% for the period 2013 to 2018.
PHM113A - Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
While the use of new drug delivery technologies for prostate cancer has increased in the past few years, there is an increasing need for new and innovative technologies related to the screening, testing, and treatment options for prostate cancer. An increasingly aging global population, R&D spending, and emerging diagnostic technologies and treatment products will drive growth in this market for the foreseeable future. BCC Research projects this market to reach $50.3 billion in 2017 after increasing at a five-year CAGR of 11.4%.
PHM045C - Global Markets for Drug-Device Combinations
Products that combine a drug or biologic with a device, such as drug-eluting stents and drug-delivery systems can offer valuable approaches for treating diseases. In addition, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery, and advanced formulation strategies are becoming the basis of even more advanced combination device strategies. Significant near-term growth in this market is being driven by technology advancements in drug-device development and improving access to health care resulting from an improving economy. BCC Research projects this market to reach $30.5 billion in 2017 after increasing at a five-year CAGR of 9.9%.
PHM005C- Global Markets for Treatment and Diagnosis of Sexually Transmitted Disease
Sexually transmitted diseases are one of the most common groups of infectious diseases worldwide. The landscape of the diagnostic market has changed significantly during the past 10 years with the development of rapid tests that can provide diagnosis of diseases such as chlamydia, gonorrhea, and syphilis in a matter of minutes rather than days or weeks. BCC Research projects this market to increase to $52 billion in 2017, and register a five-year CAGR of 9.3%.
PHM042B - Global Markets and Technologies for Pandemic Control
As infections with increasing resistance to current market drugs continue to expand both geographically and in virulence, the development of new drugs and products to combat these infections is critical to stemming the tide. BCC Research expects significant demand for viral pandemic diagnostic and pharmaceutical products to continue for the foreseeable future. BCC Research projects the market to grow to $55.6 billion by 2017, and register a five-year CAGR of 9.3% from 2012 to 2017.
Steven Cumming, BCC Research, http://www.bccresearch.com, +1 (781) 489-7301 Ext: 632, [email protected]
Share this article